Lebanese designers show off their couture creations

Updated 04 July 2018
0

Lebanese designers show off their couture creations

  • Georges Hobeika unveiled a Fall/Winter  collection that was teeming with feathers, tea-length skirts and frequent visual references to nature’s most elegant bird, the swan

DUBAI: As Haute Couture Fashion Week in Paris winds down, we are still daydreaming about the dazzling display designers from the region showcased in the culture capital.

Lebanese designer Rabih Kayrouz put on a vibrant show on Monday, sending models down the catwalk in Dorothy-inspired ginghams and daring pop art-style primary colors. Over exaggerated, frilled sleeves and a devil-may-care attitude toward mixing prints made his Spring 2019 ready-to-wear collection stand out — it was fun and instantly wearable.

Countryman Georges Hobeika took things in precisely the opposite direction, and it was breathtaking to behold. The Beirut-based designer unveiled a Fall/Winter  collection that was teeming with feathers, tea-length skirts and frequent visual references to nature’s most elegant bird, the swan. Soft, pale pinks melted into luscious, deep violets and cobalt blues in a line that was feminine and not without its quirks. 

Meanwhile, Bollywood favorite Rami Kadi unveiled an Aztec-inspired collection of pastel-hued ballgowns, as well as a wedding dress that twinkled with embedded fairy lights, iridescent ostrich feathers and wispy metallic fronds. Peaches, forget-me-not blues and cream colors, along with holographic sequins and delicate crystal embellishments, marked this collection.

Hobeika put on a stunning show. AFP


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”